The association of radioiodine therapy for the treatment of thyroid cancer with nasolacrimal duct obstruction has been well documented in the medical literature. Prior case reports have documented radioactive iodine detection in the tears of patients following radioiodine therapy. It is possible that radioactive uptake by the cells in the lacrimal sac and nasolacrimal duct lead to inflammation, fibrosis, and obstruction of the tear duct over time. A recent study has shown that the administration of artificial tears decreases the level of detectable radioiodine in the tears of patients undergoing radioiodine therapy for thyroid cancer. The purpose of this study will be to assess whether administering tears after radioactive iodine therapy for thyroid cancer decreases the incidence of nasolacrimal duct obstruction in the two years following radioactive iodine treatment.
Radio-iodine therapy for thyroid cancer
Radioiodine therapy ≥150 mCi
Age 18 or older
Use of eye drops, other than artificial tears
History of periocular trauma with tear duct involvement/lacrimal gland trauma
History of lacrimal drainage disease: canaliculitis, dacryocystitis
Prior radiotherapy
Parallel
Artificial Tears Methylcellulose
DrugParticipants will self-administer the artificial tears according to the schedule.
Incidence of Post-Radiotherapy Nasolacrimal Duct Obstruction (NLDO)
The rate of patients that developed NLDO after radioactive iodine therapy in each experimental group as determined by tear duct irrigation by an ophthalmologist.
Click on the lead sponsor to view all of their trials.
